The University has a number of Intellectual Property (IP) and Commercialisation specialists who have a wide range of technical, commercial, marketing, business, corporate finance, management and legal skills.
In today’s knowledge-based economy it is widely recognised that research, innovation and entrepreneurship are crucial driving factors for the University’s, the North East’s and the UK’s long-term efficiency, competitiveness and economic growth.
Increasingly, the UK Government has an expectation for academic research to be more aligned with industrial requirements and to generate a return on public funded investment.
It's also recognised that many medical technologies (be they new medical devices, diagnostics or therapeutics) will only ever make it to the market and deliver patient benefits/cost savings through appropriate protection, diligent management and effective commercialisation.
The Enterprise Team in the Medical School has the role of assisting University researchers to:
- identify their intellectual discoveries
- protect and support the development of these early-stage technologies
- commercialise these assets through licensing deals with existing companies or by establishing spin-out companies
Technologies for Licencing
We have a range of technologies where IP is available to licence for interested companies.
Alginate - Pancreatic Lipase Inhibitor
Alginates which are potent inhibitors of pancreatic lipase in vitro.
Antibody Efficacy and Safety Testing
Novel skin explant assay for assessment of adverse immune reactions.
Clinical Trials in Primary Biliary Cirrhosis (UK-PBC)
National Trial Resource.
Dermal Absorption and Metabolism Testing Service
Bespoke testing for clients in the cosmetic, pharmaceutical and chemical industries.
Disease Modifying Osteoarthritis Therapeutic Compounds
A compound which inhibits the serine protease enzyme matriptase.
Egg Collection Technology
Controlled environment system.
A Novel Anti-biofilm Technology.
Engineered Biomimetic Material - Cell Adhesion/Differentiation
Synthetic protein polymer which can create a range of biomimetic materials including surface coatings, hydrogels and tissue scaffolds.
Enzymatic Dispersal of Biofilms by NucB
The endonuclease NucB from a marine strain of Bacillus licheniformis: A Novel Anti-biofilm Technology.
Gene Signature for Early Diagnosis of Sero-negative Rheumatoid Arthritis
Gene signature and related methods for the diagnosis of rheumatoid arthritis (RA) in particular anti-cirullinated peptide antibody (ACPA)-negative RA.
GMP grade human fibroblast feeder cell line to progress the use of human embryonic stem cells (hESCs) derivatives for cellular therapies.
GvHD Diagnostic Biomarkers
A panel of transplantation biomarkers for prediction and diagnosis of Graft-versus-host disease.
Humanised Mice as an Evaluation Tool for Anti-Inflammatory Drugs
Reproducible murine model featuring human CD4 and CD8 T cells in blood and IgG producing B cells in the spleen.
In vitro Human Kidney Proximal Tubule Cell Model
In vitro human kidney proximal tubule cell model to predict renal drug handling and drug-drug interactions.
Intelligent Blood Pressure Measurement Device
Intelligent blood pressure measurement technology which improves the accuracy of blood pressure measurements.
Method of Inducing Bacterial Cell Membrane Synthesis
Method of inducing L-form proliferation enabling bacteria to dramatically upregulate membrane synthesis.
Models of Early Dental Biofilms
Models to culture biofilms under continuously flowing media, mimicking the continual replenishment of saliva in the mouth.
Neuro-electrodiagnostic Expansion Units and Software (NEXUS)
Low cost technology (NEXUS) which allows the recording of multi-channel (30+ channels) EMG and other peripheral signals through standard EEG systems.
A a polymer micelle platform which facilitates the safe and efficient in vivo delivery of siRNA to a target tissue.
Prognostic Test for Liver Fibrosis
A test to predict those patients who will progress to clinically significant disease from liver biopsy tissue.
Physiologically Relevant Model Gut System
In vitro Model Gut System (MGS) - simulating digestive processes of gastrointestinal (GI) tract.
Future cell based replacement therapy and in-vitro model.
Thiopurines Assay for Inflammatory Bowel Disease (IBD)
Method to detect metabolite levels in white blood cells.
Unilateral and Bimanual Dexterity Test Pegboard
Manual dexterity test which has been specifically developed for use in those with a disability affecting hand use which includes a bimanual function.
We have created a number of successful spin-out companies over the past 20 years based on the novel discoveries of our researchers and the support of the Faculty's Enterprise Team.
Some of the recent spin-out companies to be created within the Medical/Life Science/Healthcare sector are:
We run two laboratory incubator facilities for early-stage bio-technology and life sciences companies, and one office-based incubator embedded with the Newcastle University Institute for Ageing.
Our incubator facilities are designed to allow commercial organisations to interact closely with university academics, providing access (at commercial rates) to specialist facilities, whilst maintaining a clear separation from university labs.
The incubator facilities come equipped with basic laboratory and/or office space and shared communal spaces (such as kitchen and networking space). Whilst many of the tenants are University spin-outs - primarily from the Faculty of Medical Sciences - we also welcome tenants with no previous relationship with the University.
Medical School Bioincubator
The labs in the William Leech Building (at the main Medical School) are designed for smaller, earlier-stage companies, with most companies being two to five staff in size.
Centre for Life Bioincubator
Those provided in University space at the International Centre for Life are slightly larger and are more likely to be used by slightly more mature companies (although this differentiation is not rigidly enforced).
Business Innovation Facility
The Business Innovation Facility (based at the Campus for Ageing and Vitality) offers purpose-built offices of varying size, along with communal networking, meeting and kitchen spaces. This space is designed for companies who want to work with us within the emerging market created by an ageing society.
It is anticipated that the University's lab-based incubators will close in Spring 2018. This is to coincide with the opening of Newcastle Laboratory, a purpose-built commercial laboratory facility on the Science Central Site, which is being funding by Newcastle City Council, the North East LEP's Local Growth Fund, and European Structural and Investment Funds.
Enquiries regarding University incubator space should be directed to:
Telephone: +44 (0) 191 208 3583
Contact details for our Enterprise Team.
You can contact us at:
- +44 (0) 191 208 3461
Or if you are not sure that FMS is the right faculty for your query, then please contact:
- +44 (0) 191 208 2222
You can also find individual staff profiles and contact details on the Enterprise Team contact page.